Investment analysts at Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) in a research report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $98.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 32.24% from the company’s […]

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research note issued on Friday,Benzinga reports. They currently have a $124.00 price objective on the specialty pharmaceutical company’s stock. Guggenheim’s price target would suggest a potential upside of 48.01% from the company’s current price. Other research […]